

IN THE CLAIMS:

1. (cancel)
2. (currently amended) The ~~adjuvant~~ method as claimed in claim ~~[[1]]~~ 13, characterized in that the adjuvant is an adjuvant for hemogenous medicaments or active ingredients.
3. (currently amended) The ~~adjuvant~~ method as claimed in claim 2, characterized in that the adjuvant is gaseous.
4. (currently amended) The ~~adjuvant~~ method as claimed in 3, characterized in that the adjuvant is administered by inhalation.
5. (currently amended) The ~~adjuvant~~ method as claimed in claim 4, characterized in that xenon is present in a pharmacologically effective amount, in particular in an amount having a subsedative effect, sedative effect, subanalgesic activity, analgesic activity, subhypnotic activity, hypnotic activity, subanesthetic activity or anesthetic activity.
6. (currently amended) A ~~combination~~ hemogenous medicament which ~~comprises~~ includes xenon or a xenon-containing gas as an adjuvant and at least one ~~additional~~ medicament to be assisted by the adjuvant for simultaneous, separate or sequential use of the adjuvant and medicament.
7. (currently amended) The ~~combination~~ hemogenous medicament as claimed in claim 6, characterized in that the additional medicament comprises at least one medicament from the group consisting of medicaments with an antiviral, antibacterial, antimycotic, neuroprotective, anticarcinogenic, sedative, analgesically or anesthetically acting substance; opioids; sufentanil, remifentanil; anesthetics, volatile anesthetics; methoxyflurane, halothane, enflurane, isoflurane, sevoflurane and desflurane; local anesthetics; articaine, benzovaine, bupivacaine, butanilicaine, butoxycaine, cinchocaine, cocaine, etidocaine, fomocaine, lidocaine, mepivacaine, oxetacaine, oxybuprocaine, pramocaine, prilocaine, procaine, proxymetacaine, ropivacaine, tolycaine or

tetracaine; 2-adrenoceptor agonists, clonidine, dexmedetomidine; catecholamines, parasympathomimetics, parasympatholytics, spasmolytics, sympathomimetics, sympatholytics, β -receptor blocks, tranquilizers, narcoleptics, antidepressants, sedatives, centrally sedative sedating agents, analgesics, antipyretics, migraine remedies, antiparkinson agents, analeptics, antiepileptics, antiemetics, emetics, substances influencing blood clotting, amino acids, vitamins or hormones; medicaments for NOS inhibition, medicaments for treating migraine, medicaments for treating septic shock, medicaments for treating multiple sclerosis, medicaments for treating inflammations or inflammatory pains; hemogenous cerebral medicaments; medicaments for the treatment and/or prophylaxis of stroke, reperfusion damage, brain trauma, of impairments of blood flow in the brain, of impairment of cerebral perfusion, of cognitive impairments or of postischemia syndrome; barbiturates; barbitol or phenobarbital, allobarbital, amobarbital, aprobarbital, brallobarbital, cyclobarbital, pentobarbital, proallylanol, secobarbital and vinylbital, chloral hydrate, methylpentynol, paraldehyde; benzodiazepines, alprazolam, bromazepam, brotizolam, diazepam, flunitrazepam, flurazepam, lorazepam, lormetazepam, midazolam, nitrazepam, oxazepam, temazepam and triazolam; medicaments for neuroprotection, medicaments for the prophylaxis and/or therapy of impairments of cognitive performance; medicaments for Parkinson's disease, Alzheimer's disease, organic brain syndrome, ~~AIDS dementia~~, depressive pseudodementias, dementing syndromes, deliria as acute organic brain syndromes, intoxications, withdrawal syndromes or cytopathic influences; medicaments for chronic neurodegenerative disorders; medicaments for Huntington's disease, amyotrophically lateral sclerosis, Parkinson's disease, AIDS dementia, Alzheimer's disease or acute neurodegenerative disorders; medicaments for ischemias of the brain or neurotraumata; diagnostic aids, x-ray contrast agents or radioactive isotopes.

8. (cancel)

9. (currently amended) The ~~use~~ method as claimed in claim ~~[[8]]~~ 14, characterized in that the adjuvant is administered with at least one medicament for the treatment of acute and chronic cerebral disorders or impairments or a medicament for the treatment and/or prophylaxis of

ischemic brain disorders or the sequelae of a cerebral ischemia or the adjuvant is administered with at least one medicament for the treatment and/or prophylaxis of stroke, reperfusion damage or brain trauma.

10. (currently amended) The ~~adjuvant~~ method as claimed in claim ~~[[1]]~~ 13, characterized in that the adjuvant is gaseous.

11. (currently amended) The ~~adjuvant~~ method as claimed in claim ~~[[1]]~~ 13, characterized in that the adjuvant is administered by inhalation.

12. (currently amended) The ~~adjuvant~~ method as claimed in claim ~~[[1]]~~ 13, characterized in that xenon is present in a pharmacologically effective amount, in particular in an amount having a subsedative effect, sedative effect, subanalgesic activity, analgesic activity, subhypnotic activity, hypnotic activity, subanesthetic activity or anesthetic activity.

13. (new) In a method for manufacturing an adjuvant characterized in that the adjuvant comprises xenon in the form of xenon or a xenon-containing gas.

14. (new) In a method for manufacturing an adjuvant characterized in that the adjuvant is made from a xenon selected from the group consisting of xenon, xenon-containing gas and a xenon-containing preparation, where the adjuvant may be used for homogeneous medicaments or for brain-penetrating medicaments or active ingredients.